Aetna is set to sell its drug plan business to WellCare Health Plans

By Catherine Sturman
US health insurance giant Aetna has announced its plans to sell its Medicare Part D drug plan business to WellCare Health Plans for an undisclosed sum...

US health insurance giant Aetna has announced its plans to sell its Medicare Part D drug plan business to WellCare Health Plans for an undisclosed sum.

The deal forms part Aetna’s wider strategic plans to secure approval for its $69bn merger with CVS Health, which was officially announced late last year. It also follows on from Cigna’s $52bn acquisition of Pharmacy Benefit Manager (PBM) Express Scripts, which has recently been approved by federal officials, providing advantages to consumers in both insurance and PBM markets.

"We are concerned with the considerable amount of debt — over $40bn — that CVS is taking on to finance this transaction," Maria Vullo, superintendent of New York State's Department of Financial Services stated.

See also

"The considerable pressure to repay debt would cause the resulting company to repay its substantial obligation before investing in pro-market and pro-consumer measures."

This new acquisition will become WellCare’s third acquisition in two years. The move will eliminate any potential obstacles against the deal, particularly from the Department of Justice. If successful, the deal will close in the fourth quarter.

A key player in the Medicaid insurance business, the company presently serves close to three million US citizens, but will aim to scale up its activities following the merger.

 

Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals